7 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 7 of 7 clinical reviews.
A clinical deep-dive into losartan's FDA approval history, compounding legal status, label requirements, and post-market safety data. prepared by the HealthRX.com Editorial Team.
A clinical review of losartan safety signals reported through the FDA Adverse Event Reporting System (FAERS), including hyperkalemia, acute kidney injury, and nitrosamine impurity recalls.
Full FDA approval history of losartan (Cozaar), from its 1995 original approval through generic entry, pediatric labeling, LIFE trial supplemental data, and recall events.
A complete clinical and regulatory reference for losartan: FDA approval history, current prescribing label, EMA status, post-market safety findings, and what clinicians need to know in 2024.
A complete review of every FDA label change for losartan from 2020 through 2026, covering new warnings, dosing language revisions, post-market safety signals, and what the current prescribing information requires.
A clinical review of losartan's patent disputes, FDA approval timeline, NDMA recall actions, and the regulatory events that shaped ARB prescribing in the United States.
A detailed comparison of how the European Medicines Agency and U.S. Food and Drug Administration regulate losartan, including approval history, labeling differences, and post-market safety oversight.